Lymphoma Origins: When Centroblasts Go Wrong

The germinal center is simultaneously one of the most important sites of adaptive immune function and one of the most fertile grounds for B cell malignant transformation. The very features that make the GC powerful — rapid proliferation, targeted DNA mutation through AID, transient BCL2 downregulation — create conditions permissive for oncogenic events. Many of the most common B cell lymphomas have their origins in centroblasts or centrocytes that acquired transforming mutations within germinal centers.

The Three Features That Predispose GC B Cells to Transformation

First, centroblasts divide at extraordinary rates — with cell cycle times of approximately 6–12 hours — providing ample opportunity for replication errors and chromosomal instability. Second, AID activity, while primarily targeting Ig V genes, exhibits off-target activity at other genomic loci including BCL2, MYC, PAX5, and PIM1, introducing double-strand breaks and mutations at sites of potential oncogenic importance. Third, centroblasts transiently downregulate BCL2 (the anti-apoptotic guardian) — meaning cells that acquire BCL2-restoring mutations or translocations gain a survival advantage over normal GC B cells and accumulate rather than undergoing the normal apoptotic fate.

Follicular Lymphoma: The BCL2 Translocation Paradigm

Follicular lymphoma (FL) is the prototypical GC-derived B cell lymphoma. Its hallmark genetic event — the t(14;18)(q32;q21) translocation — juxtaposes the BCL2 gene (chromosome 18) to the IgH locus (chromosome 14), placing BCL2 under the control of powerful IgH enhancers. This drives BCL2 overexpression in GC B cells that normally downregulate BCL2, conferring a survival advantage that allows the transformed clone to accumulate. The t(14;18) translocation is thought to arise through AID-mediated double-strand breaks occurring simultaneously at Ig switch regions and within the major breakpoint region (MBR) of BCL2 during the GC reaction. Interestingly, the t(14;18) translocation can be detected in normal B cells from healthy adults at low frequency — indicating that this single event is insufficient for lymphomagenesis and that additional mutations are required for clinically manifest FL.

DLBCL: Two Molecular Subtypes from the GC

Diffuse large B cell lymphoma (DLBCL), the most common aggressive lymphoma, has two major subtypes with distinct GC-related origins. GCB-DLBCL (germinal center B cell-like) derives from centroblasts/centrocytes and is characterized by BCL6 translocation, EZH2 mutations (which maintain the GC B cell transcriptional program), and high BCL2 expression from amplification or t(14;18). ABC-DLBCL (activated B cell-like) derives from post-GC B cells and is characterized by constitutive NF-kappaB activation through mutations in CD79B, CARD11, or MYD88 L265P. Treatment advances including CAR-T cell therapy, polatuzumab vedotin, and novel combinations are improving outcomes in relapsed/refractory DLBCL. For the somatic hypermutation biology that precedes transformation, see our article on somatic hypermutation and high-affinity antibodies.

For more information, visit our homepage or our resources section.